Literature DB >> 3664935

Effects of verapamil on the pharmacokinetics of daunomycin in the rat.

K Nooter1, R Oostrum, J Deurloo.   

Abstract

We compared the pharmacokinetics of daunomycin in two groups of rats: one group was treated with daunomycin (7.5 mg/kg) alone and the other group was treated with daunomycin (7.5 mg/kg) plus the calcium antagonist verapamil (2 X 50 mg/kg i.p.). Due to a much slower decrease in plasma concentrations the daunomycin AUC0----infinity was dramatically increased (8 times) in the animals treated with anthracycline plus verapamil. The daunomycin plasma clearance was found to be decreased about 9 times in the verapamil-treated group. Verapamil had a differential effect on the tissue distribution of daunomycin. Of the organs examined the heart, liver, and lungs showed an increased (about 2-3 times) AUC of daunomycin. In the kidneys and spleen the AUCs of daunomycin were about equal in both groups of rats, while in the femoral bone marrow the daunomycin AUC was significantly reduced by the simultaneous administration of verapamil. Our data suggest that an increased risk for anthracycline-induced cardiotoxicity can be anticipated by the combined treatment of anthracycline drugs with calcium antagonists.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3664935     DOI: 10.1007/bf00253975

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

Authors:  E J Freireich; E A Gehan; D P Rall; L H Schmidt; H E Skipper
Journal:  Cancer Chemother Rep       Date:  1966-05

2.  The effect of verapamil on the pharmacokinetics of adriamycin.

Authors:  D J Kerr; J Graham; J Cummings; J G Morrison; G G Thompson; M J Brodie; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

Authors:  S S Legha; R S Benjamin; B Mackay; M Ewer; S Wallace; M Valdivieso; S L Rasmussen; G R Blumenschein; E J Freireich
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

4.  Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.

Authors:  K Nooter; P Sonneveld; A Martens
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

5.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

  5 in total
  5 in total

Review 1.  Multidrug resistance (MDR) genes in haematological malignancies.

Authors:  K Nooter; P Sonneveld
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats.

Authors:  C S Hughes; S L Vaden; C A Manaugh; G S Price; L C Hudson
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

3.  Daunorubicin and daunorubicinol pharmacokinetics in plasma and tissues in the rat.

Authors:  B J Cusack; S P Young; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 4.  Effects of drug transporters on volume of distribution.

Authors:  Anita Grover; Leslie Z Benet
Journal:  AAPS J       Date:  2009-04-28       Impact factor: 4.009

Review 5.  Multidrug resistance (mdr) genes in human cancer.

Authors:  K Nooter; H Herweijer
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.